Thoracic Malignancy Steering Committee
The NCI Thoracic Malignancy Steering Committee (TMSC) was established in 2008.
The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase 3 trials and large phase 2 studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma. Esophageal cancer trials are reviewed by the Gastrointestinal Cancer Steering Committee.
Clinical Trials Planning Meetings (CTPMs)
- Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer – February 2012
- Consensus Report of a Joint NCI/FDA Workshop Leading to the Inception of “Master Protocols” in Lung Cancer – Journal of Thoracic Oncology
The following are clinical trials that were approved at the concept stage by the Steering Committee:
|Trial ID||NCT ID||Trial Title|
|RTOG-0937||NCT01055197||Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)|
CCCT Contact: Wolf Lindwasser, Ph.D.